Stock Suspensions/Halts 01/09/2018 Effective Date Symbol

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
101
Stock Suspensions/Halts 01/09/2018

Effective Date Symbol Company Name Security Type Venue Status
Jan 8, 2018 VPTDF VentriPoint Diagnostics Ltd. Ordinary Shares OTC Link Halted
Jan 8, 2018 UBIA UBI BlockChain Internet Ltd. Common Stock OTC Link Suspended
Jan 8, 2018 MXRSF Malbex Resources, Inc. Ordinary Shares Grey Market Halted
Jan 8, 2018 LGDTF Liberty Gold Corp Ordinary Shares OTC Link Halted
Jan 8, 2018 ITMZF Intema Solutions Inc. Ordinary Shares Grey Market Halted
Jan 8, 2018 IMMU Immunomedics, Inc. Common Stock Nasdaq Halted
Jan 8, 2018 HYYDF Hydropothecary Corp Ordinary Shares Grey Market Halted
Jan 8, 2018 GPRO GoPro, Inc. Common Stock Nasdaq Halted
Jan 8, 2018 GPRO GoPro, Inc. Common Stock Nasdaq Halted
Jan 8, 2018 GPACW Global Partner Acquisition Corp. Warrants Nasdaq Halted
Jan 8, 2018 GPACU Global Partner Acquisition Corp. Units Nasdaq Halted
Jan 8, 2018 GPAC Global Partner Acquisition Corp. Common Stock Nasdaq Halted
Jan 8, 2018 DDBXF Data Deposit Box, Inc. Ordinary Shares OTC Link Halted
Jan 8, 2018 BRT BRT Apartments Corp. Fund NYSE Halted
Jan 5, 2018 NXXYF NYX Gaming Group Ltd. Ordinary Shares Grey Market Halted
Jan 5, 2018 NWURF Captor Cap Corp. Ordinary Shares OTC Link Halted
Jan 5, 2018 IVITF Invictus MD Strategies Corp. Ordinary Shares OTC Link Halted
Jan 4, 2018 S Sprint Corporation Common Stock NYSE Halted
Jan 4, 2018 PKE Park Electrochemical Corp. Common Stock NYSE Halted
Jan 4, 2018 MYAGF Maya Gold & Silver Inc. Ordinary Shares Grey Market Halted
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading